Literature DB >> 10094252

Clinicopathological features of Churg-Strauss syndrome-associated neuropathy.

N Hattori1, M Ichimura, M Nagamatsu, M Li, K Yamamoto, K Kumazawa, T Mitsuma, G Sobue.   

Abstract

We assessed the clinicopathological features of 28 patients with peripheral neuropathy associated with Churg-Strauss syndrome. Initial symptoms attributable to neuropathy were acute painful dysaesthesiae and oedema in the dysaesthetic portion of the distal limbs. Sensory and motor involvement mostly showed a pattern of mononeuritis multiplex in the initial phase, progressing into asymmetrical polyneuropathy, restricted to the limbs. Parallel loss of myelinated and unmyelinated fibres due to axonal degeneration was evident as decreased or absent amplitudes of sensory nerve action potentials and compound muscle action potentials, indicating acute massive axonal loss. Epineurial necrotizing vasculitis was seen in 54% of cases; infiltrates consisted mainly of CD8-positive suppressor/cytotoxic and CD4-positive helper T lymphocytes. Eosinophils were present in infiltrates, but in smaller numbers than lymphocytes. CD20-positive B lymphocytes were seen only occasionally. Deposits of IgG, C3d, IgE and major basic protein were scarce. The mean follow-up period was 4.2 years, with a range of 8 months to 10 years. Fatal outcome was seen only in a single patient, indicating a good survival rate. The patients who responded well to the initial corticosteroid therapy within 4 weeks regained self-controlled functional status in longterm follow-up (modified Rankin score was < or = 2), while those not responding well to the initial corticosteroid therapy led a dependent existence (P < 0.01). In addition the patients with poor functional outcomes had significantly more systemic organ damage caused by vasculitis (P < 0.05). Necrotizing vasculitis mediated by cytotoxic T cells, leading to ischaemic changes, appears to be a major cause of Churg-Strauss syndrome-associated neuropathy. The initial clinical course and the extent of systemic vasculitic lesions may influence the long-term functional prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094252     DOI: 10.1093/brain/122.3.427

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  41 in total

1.  Expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFR alpha, LIFR beta, IL-6R alpha, and gp130) in human peripheral neuropathies.

Authors:  Y Ito; M Yamamoto; N Mitsuma; M Li; N Hattori; G Sobue
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Churg-Strauss vasculitis diagnosed on muscle biopsy.

Authors:  E Suresh; V B Dhillon; C Smith; J W Ironside
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

3.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

Authors:  M G Danieli; M Cappelli; G Malcangi; F Logullo; A Salvi; G Danieli
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

4.  Acute painless monocular visual loss due to central retinal artery occlusion in a patient with Churg-Strauss vasculitis.

Authors:  Ioanna Skrapari; Eleftheria Kagkelari; Evangelos Charitatos; Catherine Pantelidaki; Theodoros Gounaris; Evagelia Sioula
Journal:  Clin Rheumatol       Date:  2007-08-04       Impact factor: 2.980

Review 5.  Primary and secondary vasculitic neuropathy.

Authors:  Gérard Said; Catherine Lacroix
Journal:  J Neurol       Date:  2005-04-05       Impact factor: 4.849

6.  Polyneuropathy with demyelinating changes in Churg-Strauss syndrome: an unusual association.

Authors:  A R Pati; P L Capecchi; A Malandrini; A Federico; A Mignarri
Journal:  Neurol Sci       Date:  2016-12-26       Impact factor: 3.307

Review 7.  Diagnosis and therapeutic options for peripheral vasculitic neuropathy.

Authors:  Franz Blaes
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-04       Impact factor: 5.346

8.  [A patient with Churg-Strauss syndrome presenting as Guillain-Barré syndrome].

Authors:  M Djukic; H Schmidt; C Mazurek; F König; S Schweyer; R Nau
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

Review 9.  Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Haruki Koike; Gen Sobue
Journal:  Clin Exp Nephrol       Date:  2013-02-06       Impact factor: 2.801

Review 10.  Peripheral neuropathies in rheumatic disease--a guide to diagnosis.

Authors:  Jean-Michel Vallat; Magalie Rabin; Laurent Magy
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.